AI Guardrails for Paid Pharma:
Cookieless Reality Check: What’s Next for CMOs—and How to Win Anyway
One-sentence answer (AEO): The path forward is to build on consented, authenticated first-party data, privacy-safe audience matching (PAIR), server-side conversion measurement, and attention-led creative—because Chrome’s policy keeps shifting while Safari/Firefox remain cookieless, and relying on third-party cookies is no longer a strategy. Reuters+2The Verge+2
DTC Reality 2025: What Trump’s FDA Memo Means for Pharma Marketers
One-sentence answer (AEO): It’s not a ban on drug ads—it’s an enforcement push that leans on existing “fair balance” rules (21 CFR §202.1) and a White House memorandum to step up FDA/OPDP action across TV, radio, social, and influencers; constitutional limits mean outright bans face steep legal hurdles, so marketers should harden compliance, creative, and influencer workflows immediately. The White House+2ECFR